



PRESS RELEASE

31 May 2008

Zilico appoints new non-executive directors & medical advisory board

A former medical director with pharmaceutical & healthcare giant Boots and the first chief executive of the Central Technology Belt have joined the board of Zilico Ltd as non-executive directors.

Dr Helen Shaw and Dr Alan Folwell will be bringing a wealth of expertise to help Zilico press ahead with developing devices to assist with cervical cancer screening.

Dr Shaw worked for Boots Healthcare International until January 2006 when it was acquired by Reckitt Benckiser. Helen is also a non-executive director of drug R&D company Syntopix plc.

Dr Folwell brings extensive business experience to Zilico, following a range of senior roles in manufacturing and technology-based industries. Alan's particular interests are in fostering and developing technology- and knowledge-based activities and he retains a position as special adviser to the Central Technology Belt.

Sameer Kothari, CEO of Zilico Ltd., said: "I am delighted to welcome Helen and Alan to the board. Helen's experience at Boots and Alan's commercial experience within high-technology SMEs will be invaluable to Zilico"

Zilico Ltd. has also appointed four medical experts to its Medical Advisory Board:

Professor Walter Prendeville - Consultant Obstetrician/Gynaecologist Coombe Women's Hospital, Dublin

Dr Maggie Cruickshank - Consultant Obstetrician/Gynaecologist Aberdeen Royal Infirmary, Aberdeen

Mr John Smith - Consultant Histopathologist and Cytopathologist, Royal Hallamshire Hospital, Sheffield

The Board will be chaired by Mr John Tidy, Consultant Gynaecologist at the Royal Hallamshire Hospital, Sheffield, and clinical founder of Zilico.

For more information please contact:

Sameer Kothari, CEO, Zilico Ltd, tel: 0114 222 4580; mobile: 07736 403872; email: sameer.kothari@zilico.co.uk



PRESS RELEASE

Notes for editors:

Zilico Ltd is a company developing the next generation of cancer diagnostics with a product line which will provide real-time diagnostics for cervical cancer. Two products are under development: the first for the referral market and the second for the screening market. Clinical data on 500 women has demonstrated superior performance over existing diagnostic procedures and a multi-centre clinical trial over the next 8 months is expected to underwrite the effectiveness of Zilico's technology and products.

Zilico has developed Electrical Impedance Spectroscopy EIS, an objective scientifically-proven method to differentiate between normal, pre cancerous and cancerous cells. This provides a real-time diagnosis that removes subjectivity at both screening and referral, and potentially avoids the need for a biopsy. Zilico's patented technology, which has been discussed in learned peer-reviewed journals, exploits the different electrical resistivity of normal, pre-cancerous and cancerous cells.

Since incorporation in 2006, Zilico (previously known as Aperio Diagnostic Ltd) has focused on developing a research-based instrument into a device appropriate for commercial manufacture and routine use by medical practitioners. Both Zilico products consist of a handheld device and a base unit together with a single-use disposable sleeve for each test. Pre-production standard devices will be used in a multi centre clinical trial scheduled to start in Q3 2008.